Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Danbury program focuses on student career prep

Career fairs, college visits, job shadows and internships may become part of the regular high school experience in Danbury over the next few years. This...

| By Kelley Gipson

Programs mark 50 years of BI presence in the US

Boehringer Ingelheim, in partnership with Yale University, has announced the launch of a Biomedical Data Science Fellowship program designed to attract and support some of...

| By Kelley Gipson

UConn TIP and neuro research recognized

The UConn Technology Incubation Program (TIP) has received the Randall M. Whaley Award from the International Business Innovation Association (InBIA) recognizing their outstanding achievement as...

| By Kelley Gipson

Sen. Murphy names AI ‘Innovator of the Month’

U.S. Senator Chris Murphy (D-Conn.) has named AI Therapeutics, based in Guilford, “Innovator of the Month.” Founded by Dr. Jonathan Rothberg in 2013 to advance...

| By Kelley Gipson

Pharma execs urge cooperation, not patent waivers

The pharmaceutical industry has shown leadership and resolve in providing vaccines for COVID-19. The industry is ready to continue working with the administration, world leaders,...

| By Kelley Gipson

Management additions at EvolveImmune, CytoVeris

EvolveImmune Therapeutics reports that Ian Taylor, PhD, has joined its board of directors. Dr. Taylor is a veteran biopharma executive who currently serves as the...

| By Kelley Gipson

Bilenker, Engelman create Treeline Biosciences

Josh Bilenker, M.D., and Jeff Engelman M.D., Ph.D., have joined forces to create a new cancer biotech, tapping their combined considerable experience to find new...

| By Kelley Gipson

CaroGen awarded $3 million Phase 2b SBIR grant

CaroGen Corporation has been awarded a $3 million Phase 2b SBIR grant from the National Institutes of Health (NIH) to advance its lead clinical candidate...

| By Kelley Gipson

Astrocyte raises $6M re stroke and TBI treatments

Astrocyte Pharmaceuticals reports the completion of a Series A financing that raised $6.0M. Astrocyte is progressing its lead development candidate AST-004 to address the unmet...